Second Genome Presents Preclinical Data Highlighting Potential Therapeutic Implications of Altered Gut Microbiome and Metabolites in Autism Spectrum Disorder Model and Parkinson’s Disease at The Society for Neuroscience Annual Meeting
- Thursday, November 11, 2021, 7:00
- Finance
- Add a comment
BRISBANE, Calif., Nov. 11, 2021 /PRNewswire/ — Second Genome, a biotechnology company that leverages its proprietary platform sg-4sight to discover and develop precision therapies and biomarkers, presented two posters at the Society for Neuroscience’s (SfN) 50th Annual Meeting…
About the Author
adminasapcorp has written 41562 stories on this site.